Category Specific RSS

pxs

Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled

Aussies are some of the most enthusiastic adopters of new clinical drugs. In 2019, 95,000 of us participated in nearly…

2 years ago

Pharmaxis cancer drug progress detailed at leading scientific conference, eyes FDA discussions in 2023

Having delivered impressive interim trial data from their Phase 2 clinical trials for a treatment targeting incurable bone marrow cancer,…

3 years ago

Platinum Asset Management identify value opportunity in Pharmaxis with $1.9m stake

When it comes to biotech investing, the value opportunities in Australia attract many of the world's smartest investors. Amongst them,…

3 years ago

Opening a new frontier in treating Parkinson’s disease

More than 100,000 people in Australia live with Parkinson’s—a central nervous system disorder affecting one’s movement and mood. It is…

3 years ago

Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler

Aptar Pharma has deemed now the perfect time to exercise their option to purchase an inventive piece of Pharmaxis’ (ASX:…

3 years ago